A randomized, open-label, single-dose, 4-period crossover, comparative bioavailability study of 3 sustained-release formulations and an immediate-release formulation of vabicaserin (SCA-136) in healthy subjects

Trial Profile

A randomized, open-label, single-dose, 4-period crossover, comparative bioavailability study of 3 sustained-release formulations and an immediate-release formulation of vabicaserin (SCA-136) in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2007

At a glance

  • Drugs Vabicaserin (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 19 Oct 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top